<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02249000</url>
  </required_header>
  <id_info>
    <org_study_id>C1205</org_study_id>
    <nct_id>NCT02249000</nct_id>
  </id_info>
  <brief_title>BIOVALVE - I / II Clincial Investigation</brief_title>
  <acronym>BIOVALVE</acronym>
  <official_title>Safety and Clinical Performance of the Self-expanding Transcatheter BIOVALVE Prosthesis in Subjects With Severe Symptomatic Aortic Stenosis Suitable for Transfemoral Transcatheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biotronik AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      First-in-Human clinical investigation to evaluate the safety and clinical performance of the
      BIOVALVE prosthesis in subjects presenting with severe symptomatic aortic valve stenosis,
      which are as judged by the heart team, indicated for transfemoral transcatheter aortic valve
      implantation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a non-randomized, prospective, multi-center clinical investigation, approximately 86
      eligible subjects will be enrolled.

      Phase 1: BIOVALVE-I feasibility clinical investigation: Approximately 13 eligible subjects
      will be enrolled.

      Phase 2: BIOVALVE-II pilot clinical investigation: Approximately 73 eligible subjects will be
      enrolled.

      BIOVALVE-I/II subjects follow the same clinical investigation plan (CIP) in all aspects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early safety at 30 days (Acc. to VARC-2)</measure>
    <time_frame>30 days</time_frame>
    <description>A composite of all-cause mortality, all stroke (disabling/non-disabling), life-threatening bleeding, acute kidney injury stage 2 or 3 (including renal replacement therapy), coronary artery obstruction requiring intervention, major vascular complication and valve-related dysfunction requiring repeat procedure (balloon aortic valvuloplasty (BAV), transcatheter aortic valve implantation (TAVI), or surgical aortic valve replacement (SAVR)).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined safety endpoint at 30 days (Acc. to VARC-1)</measure>
    <time_frame>30 days</time_frame>
    <description>A composite of all-cause mortality, major stroke, life-threatening (or disabling) bleeding, acute kidney injury stage 3 (including renal replacement therapy), peri-procedural myocardial infarction, major vascular complication and repeat procedure for valve-related dysfunction (surgical or interventional therapy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy after 30 days (Acc. to VARC-2):</measure>
    <time_frame>30 days</time_frame>
    <description>A composite of all-cause mortality, all stroke (disabling and non-disabling), requiring hospitalizations for valve-related symptoms or worsening congestive heart failure, NYHA class III or IV, valve-related dysfunction (mean aortic valve gradient ≥20 mm Hg, effective orifice area (EOA) ≤0.9-1.1 cm2 * and/or Doppler velocity index (DVI) &lt;0.35 m/s, and/or moderate or severe prosthetic valve regurgitation **).
* depending on body surface area
** refers to VARC-2 definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiograhic (ECHO) parameters</measure>
    <time_frame>Discharge, 30 days, 6 months, 12 months and annually through 5 years</time_frame>
    <description>Effective orifice area (EOA) and effective orifice area index (EOAI) Mean prosthetic valve gradient Prosthetic valve regurgitation (Acc. to VARC-1 and VARC-2)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Heart Valve Diseases</condition>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>BIOVALVE prosthesis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter Aortic Valve Replacement (TAVR)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BIOVALVE prosthesis</intervention_name>
    <description>Transcatheter Aortic Valve Replacement (TAVR)</description>
    <arm_group_label>BIOVALVE prosthesis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject is ≥65 years

          2. The subject has provided written informed consent

          3. Subject is willing to participate in the clinical investigation and to comply with all
             of the study procedures and follow-up visits

          4. NHYA class ≥II

          5. High surgical risk: Logistic EuroSCORE-I ≥20% (or equivalence of EuroSCORE-II) or STS
             score ≥10% or co-morbidity judged by the heart team (consisting of at least one
             interventional cardiologist and one cardiac surgeon) to pose an absolute or relative
             contraindication for conventional aortic valve replacement according to VARC-2

          6. Severe symptomatic calcific aortic valve stenosis characterized by mean aortic
             gradient &gt;40 mm Hg or peak jet velocity &gt;4.0 m/s or effective orifice area (EOA) of
             &lt;1.0 cm2 (&lt;0.6 cm2/m2 body surface area)

          7. Annulus diameter as determined by multi-slice computed tomography (MSCT) from 23-26 mm

        Exclusion Criteria:

          1. Trans-esophageal echocardiogram (TEE) is contraindicated

          2. Congenital bicuspid or unicuspid valve

          3. Left ventricular outflow tract (LVOT) obstruction such as hypertrophic obstructive
             cardio myopathy (HOCM) or subject presenting with systolic anterior motion (SAM).
             Evidence of intra cardiac mass, thrombus or vegetation

          4. Transfemoral access vessel characteristics that would preclude safe placement of a 18
             French sheath

          5. Vessel and/or anatomical characteristics that would preclude safe delivery of the
             BIOVALVE prosthesis to the ascending aorta and/or placement of the prosthesis

          6. Anatomical restrictions such as shallow sinuses with heavily calcified leaflets, low
             height of coronary ostia, extreme tortuosity of the aortic arch, thoracic (TAA) or
             abdominal (AAA) aortic aneurysm, presence of endovascular stent graft

          7. Severe mitral regurgitation grade &gt;3

          8. Severe mitral stenosis

          9. Prosthetic mitral valve

         10. Severe left ventricular dysfunction with left ventricular ejection fraction (LVEF)
             &lt;20%

         11. Hemodynamic instability

         12. Percutaneous coronary intervention (PCI) within 30 days prior to index procedure and /
             or planned PCI during index procedure

         13. Renal insufficiency (creatinine &gt;2.5 mg/dl) or subject under dialysis and/or renal
             replacement therapy

         14. Any cerebrovascular event or transient ischemic attack (TIA) within 180 days prior to
             TAVI procedure

         15. Evidence of acute myocardial infarction (defined as ≥2 fold CK level or in absence of
             CK a ≥3 fold CKMB level above the upper range limit within ≤30 days prior to TAVI
             procedure)

         16. Blood dyscrasia defined as: leucopenia (WBC &lt;1000 mm³), thrombocytopenia (platelet
             count &lt;50'000 cells/mm³), history of bleeding diathesis requiring blood transfusion

         17. Ongoing sepsis or suspected active endocarditis

         18. Active peptic ulcer or gastrointestinal bleeding within last 3 months that would
             preclude anticoagulation

         19. Subject refuses blood transfusion

         20. Known hypersensitivity to, or contraindication to nitinol,
             anticoagulation/antiplatelet regimes, any other medications required for the procedure
             or post-procedure as determined by the heart team, or sensitivity to contrast media
             which cannot be adequately pre-medicated

         21. Need for emergency TAVI intervention, or other medical, social, or psychological
             conditions that in the opinion of the heart team precludes the subjects from
             appropriate consent or adherence to protocol required follow-up exams

         22. Expectation that subject will not improve despite treatment of aortic stenosis

         23. Estimated life expectancy of less than 12 months due to associated non-cardiac
             co-morbidities

         24. Severe pulmonary hypertension (&gt; 60 mm Hg assessed by continuous wave Doppler, TTE) or
             clinical signs of acute severe right ventricular dysfunction

         25. Currently participating in another investigational drug or device study where primary
             endpoint has not been reached yet
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hendrik Treede, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitätsklinikum Halle (Saale), Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrich Schaefer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Heart Center Hamburg, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karin Lussi</last_name>
    <phone>+41448645435</phone>
    <email>karin.lussi@biotronik.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Myriam Stieler</last_name>
    <phone>+ 41448645517</phone>
    <email>myriam.stieler@biotronik.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Verheye, MD</last_name>
      <phone>+3232803255</phone>
      <email>stefan.verheye@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Paul Vermeersch</last_name>
      <phone>+3232803255</phone>
      <email>paul.vermeersch@zna.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Städtische Kliniken Neuss - Lukaskrankenhaus</name>
      <address>
        <city>Neuss</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41464</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Haude, MD</last_name>
      <phone>+49 21 31 888 2001</phone>
      <email>mhaude@lukasneuss.de</email>
    </contact>
    <contact_backup>
      <last_name>Hubertus Degen, MD</last_name>
      <phone>+49 21 31 888 2001</phone>
      <email>hdegen@lukasneuss.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Segeberger Kliniken</name>
      <address>
        <city>Bad Segeberg</city>
        <state>Schleswig-Holstein</state>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Abdel-Wahab, MD</last_name>
      <phone>+49 45 51 80 24 801</phone>
      <email>mohamed.abdel-wahab@segebergerkliniken.de</email>
    </contact>
    <contact_backup>
      <last_name>Gert Richardt, MD</last_name>
      <phone>+49 45 51 80 24 801</phone>
      <email>gert.richardt@segebergerkliniken.de</email>
    </contact_backup>
    <investigator>
      <last_name>Bettina Schwarz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed El-Mawardy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Kische, MD</last_name>
      <phone>+49 30 130 23 1997</phone>
      <email>stephan.kische@vivantes.de</email>
    </contact>
    <contact_backup>
      <last_name>Hüseyin Ince, MD</last_name>
      <phone>+49 30 130 23 1997</phone>
      <email>hueseyin.ince@vivantes.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>German Heart Center</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volkmar Falk, MD</last_name>
      <phone>+ 49 30 4593 2000</phone>
      <email>falk@dhzb.de</email>
    </contact>
    <contact_backup>
      <last_name>Jörg Kempfert, MD</last_name>
      <phone>+49 30 4593 2084</phone>
      <email>kempfert@dhzb.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale)</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hendrik Treede, MD</last_name>
      <phone>+493455572719</phone>
      <email>Hendrik.Treede@UK-Halle.de</email>
    </contact>
    <contact_backup>
      <last_name>Stefan Frantz, MD</last_name>
      <phone>+493455572601</phone>
      <email>stefan.frantz@uk-halle.de</email>
    </contact_backup>
    <investigator>
      <last_name>Efstratios Charitos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulrich Hofmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jochen Schröder, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miriam Silaschi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Frerker, MD</last_name>
      <phone>+49401818854429</phone>
      <email>c.frerker@asklepios.com</email>
    </contact>
    <contact_backup>
      <last_name>Karl-Heinz Kuck, MD</last_name>
      <phone>+49401818852305</phone>
      <email>k.kuck@asklepios.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tobias Schmidt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Heart Center</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Schaefer, MD</last_name>
      <phone>+4940741053979</phone>
      <email>u.schaefer@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Lenard Conradi, MD</last_name>
      <phone>+4940741053440</phone>
      <email>lconradi@uke.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Heart Center</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Baldus, MD</last_name>
      <phone>+ 49 221 478 32511</phone>
      <email>stephan.baldus@uk-koeln.de</email>
    </contact>
    <contact_backup>
      <last_name>Thorsten Wahlers, MD</last_name>
      <phone>+49 221 478-325 08</phone>
      <email>thorsten.wahlers@uk-koeln.de</email>
    </contact_backup>
    <investigator>
      <last_name>Tanja Rudolph, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Volker Rudolf, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Navid Mader, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maximilian Scherner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elmar Kuhn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Linke, MD</last_name>
      <phone>+493418651426</phone>
      <email>Axel.Linke@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>David Holzhey, MD</last_name>
      <phone>+493418651421</phone>
      <email>dholzhey@web.de</email>
    </contact_backup>
    <investigator>
      <last_name>Norman Mangner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hueseyin Ince, MD</last_name>
      <phone>+493814947701</phone>
      <email>hueseyin.ince@med.uni-rostock.de</email>
    </contact>
    <contact_backup>
      <last_name>Mohammad Sherif, MD</last_name>
      <phone>+493814947795</phone>
      <email>mohammad.sherif@med.uni-rostock.de</email>
    </contact_backup>
    <investigator>
      <last_name>Alper Oener, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina-Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W.A.L Tonino, MD</last_name>
      <phone>+31402397004</phone>
      <email>pim.tonino@cze.nl</email>
    </contact>
    <contact_backup>
      <last_name>B.R.G. Brueren, MD</last_name>
      <email>guus.brueren@catharinaziekenhuis.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Maisano, MD</last_name>
      <phone>+41442553298</phone>
      <email>francesco.maisano@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Fabian Nietlispach, MD</last_name>
      <phone>+41442558599</phone>
      <email>Fabian.Nietlispach@usz.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Maurizio Taramasso, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodés-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB; Valve Academic Research Consortium-2. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. EuroIntervention. 2012 Nov 22;8(7):782-95. doi: 10.4244/EIJV8I7A121.</citation>
    <PMID>23022744</PMID>
  </reference>
  <reference>
    <citation>Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, Kappetein AP, Krucoff MW, Mack M, Mehran R, Miller C, Morel MA, Petersen J, Popma JJ, Takkenberg JJ, Vahanian A, van Es GA, Vranckx P, Webb JG, Windecker S, Serruys PW. Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol. 2011 Jan 18;57(3):253-69. doi: 10.1016/j.jacc.2010.12.005. Epub 2011 Jan 7.</citation>
    <PMID>21216553</PMID>
  </reference>
  <results_reference>
    <citation>Treede H, Lubos E, Conradi L, Deuschl F, Asch FM, Weissman NJ, Schofer N, Schirmer J, Koschyk D, Blankenberg S, Reichenspurner H, Schaefer U. Thirty-day VARC-2 and performance data of a new self-expanding transcatheter aortic heart valve. EuroIntervention. 2015 Nov;11(7):785-92. doi: 10.4244/EIJY15M05_05.</citation>
    <PMID>25983028</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2014</study_first_submitted>
  <study_first_submitted_qc>September 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2014</study_first_posted>
  <last_update_submitted>February 15, 2017</last_update_submitted>
  <last_update_submitted_qc>February 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

